Structure-activity relationship of N-[2-(dimethylamino)-6-[3-(5-methyl-4-phenyl-1H-imidazol-1-yl)propoxy]phenyl]-N'-pentylurea and analogs. Novel potent inhibitors of acyl-CoA:cholesterol O-acyltransferase with antiatherosclerotic activity
作者:Teiji Kimura、Yasutaka Takase、Kenji Hayashi、Hiroshi Tanaka、Issei Ohtsuka、Takao Saeki、Motoji Kogushi、Toshie Yamada、Tohru Fujimori
DOI:10.1021/jm00063a013
日期:1993.5
urea (4), a novel, potent, and systemically bioavailable inhibitor of ACAT (acylCoA:cholesterol O-acyltransferase). The structure-activity relationships (SARs) of this lead compound 4 were investigated by systematic modification of four regions in the molecule. The compounds prepared in this study were tested for in vitro inhibitory activity toward both aortic and intestinal ACATs, and selected compounds
我们发现了一种新颖,有效的N-丁基-N'-[2-(二甲基氨基)-6- [3-(4-苯基-1H-咪唑-1-基)丙氧基]苯基]脲(4)全身可利用的ACAT抑制剂(酰基CoA:胆固醇O-酰基转移酶)。通过系统修饰分子中的四个区域,研究了该先导化合物4的构效关系(SAR)。测试了本研究中制备的化合物对主动脉和肠道ACAT的体外抑制活性,并进一步测试了所选化合物的体内降胆固醇活性。这些研究不仅导致发现了N- [2-(二甲基氨基)-6- [3-(5-甲基-4-苯基-1H-咪唑-1-基)丙氧基]苯基] -N'-戊脲( 24),口服后具有有效的活性和适度的血浆水平,而且还揭示了每个修饰区域的SAR。进一步选择了四种化合物(4、13、14、24)来测试体内抗动脉粥样硬化活性。4、13和24将动脉粥样硬化斑块的形成减少到对照面积的38-45%,而14则没有明显的抗动脉粥样硬化作用。